Transparency
The whole supply chain, end to end. Pharma-grade GMP manufacturers that licensed pharmacies source from, the research-use retailers in the consumer channel, and the FDA enforcement timeline that has reshaped the market in 2024–2026.
Pharma-grade · GMP · B2B
GMP-certified API manufacturers and CDMOs that supply FDA-registered drug companies and 503A/503B compounding pharmacies. MOQs are typically grams to kilos; pricing is contract-based. Not retail.
Premier peptide CDMO. Grams-to-tons GMP production with comprehensive regulatory documentation across major markets.
Six GMP facilities across five countries. Generic GMP peptides plus custom synthesis for clinical and commercial supply.
Full-service GMP CDMO for peptides, HPAPIs, and complex modalities. Boulder facility is the largest worldwide peptide API producer.
150+ years of API process development and commercial manufacturing. Custom synthesis at clinical and commercial scale.
Global CRDMO platform. 32,000 L total solid-phase peptide synthesis reactor volume after 2024 expansion.
cGMP peptide synthesis with no minimum order quantity. Lab-scale process dev → pilot → GMP manufacturing.
Boutique Swiss peptide CDMO. Custom synthesis with European pharma compliance posture.
One of the larger synthetic peptide manufacturers in China. EP/USP-standard products for biochemical research and API use.
Research-use retailers
Direct-to-consumer vendors operating under a "research use only — not for human consumption" disclaimer. The category is under active FDA enforcement.
Selling these products for human use without a prescription remains illegal in the US. PeptaRx sources from Direct Peptides (first below).
Our upstream supplier. UK-based research-peptide retailer with public per-mg pricing, worldwide tracked shipping, and 24–48h dispatch.
Largest US-based research catalog: 90+ peptides. Batch-specific COAs, HPLC/LC-MS testing, sterility screening, 30-day refund.
Multi-form catalog: liquid, powder, capsule, tablet variants. Markets 99% purity with COAs.
Top of PepPal's Finnrick directory by independent test volume — 59 samples vs ~13 for nearest competitor.
Surfaces in 2026 vendor lists as a still-operating compliant alternative after the wave of shutdowns.
Broad catalog spanning peptides, SARMs, nootropics, ancillaries. Documentation posture stronger than typical for the category.
Regulatory state · 2026
The peptide retail market is consolidating fast. Major vendors have shut down, been raided, or received warning letters. This is the live timeline.
2024-12
FDA warning letters: Prime Peptides, Xcel Peptides, SwissChems, Summit Research.
2025-06
Amino Asylum warehouse raided by FDA agents.
2026-03-06
Peptide Sciences voluntarily shut down — largest gray-market US vendor offline.
2026-04-07
FDA publishes seven warning letters against research-use peptide sellers in a single day.
2026
Policy Canary tracks 175+ FDA warning letters year-to-date in the peptide category.